コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 as used when patients did not respond to the steroid treatment.
2 glucocorticoid-sensitive 6TG1.1 cells before steroid treatment.
3 ses in group B; none were reversible despite steroid treatment.
4 eficient states such as diabetes, and during steroid treatment.
5 chronic rejection and was down-regulated by steroid treatment.
6 n challenge and decrease in asthmatics after steroid treatment.
7 midine incorporation was observed 24 h after steroid treatment.
8 al iNOS levels may reflect responsiveness to steroid treatment.
9 asis of the need or not for systemic cortico-steroid treatment.
10 rtality among patients who do not respond to steroid treatment.
11 mber amplifications, AR splice-variants, and steroid treatment.
12 and AHR that were partially reversible with steroid treatment.
13 utochthonous hepatitis E that resolved under steroid treatment.
14 venting AECOPD requiring both antibiotic and steroid treatment.
15 tion language, or type, dose, or duration of steroid treatment.
16 30 rejection episodes (73.3%) resolved with steroid treatment.
17 cial effect is synergistically enhanced with steroid treatment.
18 d retinal ganglion cells during intravitreal steroid treatment.
19 completely unresponsive to IVIG or high-dose steroid treatment.
20 nt) but progressed in three patients without steroid treatment.
21 r steroid treatment but can progress without steroid treatment.
22 t, ERbeta mRNA levels were unaffected by any steroid treatment.
23 on with progressive symptoms despite ongoing steroid treatment.
24 and persisted despite the cessation of oral steroid treatment.
25 ecovery of thymic function after a course of steroid treatment.
26 esses, duration of Crohn disease, and use of steroid treatment.
27 cations for evaluating patients on high-dose steroid treatment.
28 assist efforts to reduce the side effects of steroid treatments.
29 eas NO concentrations were not influenced by steroid treatment (3.0 +/- 0.4 ppm and 2.9 +/- 0.2 ppm,
30 trations were also higher in patients not on steroid treatment (3.4 +/- 0.2 ppm) than in steroid-trea
32 to standard treatment and may substitute for steroid treatments aimed at controlling disease activity
33 n graft survival was seen compared with both steroid treatment alone (P < 0.05) and steroid combined
36 utations in NPHS2 do not respond to standard steroid treatment and have a reduced risk for recurrence
38 te rejection, which were reversed with bolus steroid treatment, and four were donor-specific antibody
39 iseases involving bone marrow, no history of steroid treatment, and no other risk factors for osteone
41 nically recognized as asthma, was quelled by steroid treatment, and was unmasked following corticoste
42 id a post-hoc analysis of the 3 year inhaled Steroid Treatment As Regular Therapy (START) study, done
44 aging approach revealed that bevacizumab and steroid treatment blocked leukocyte infiltration into im
46 ons in 10 patients regressed (in nine, after steroid treatment) but progressed in three patients with
49 immediately recovered following cessation of steroid treatment, concurrent with restoration of the th
50 tivation and found that both denervation and steroid treatment contribute to the shift in inactivatio
51 r, or Pseudomonas aeruginosa infection, oral steroid treatment decreased Glut1 and PiT2 levels in blo
52 oxide, blood eosinophil counts, and inhaled steroid treatment did not influence cough parameters.
54 as associated with the delayed initiation of steroid treatment for GVHD (0.95 months vs 3.0 months; P
55 ne average at 2 months was 56.0 for the oral steroid treatment group and 57.6 dB for the intratympani
58 that is chronic in nature or uncontrolled by steroid treatment have shown good response to immunosupp
59 clonal bands (OCB) and beneficial effects of steroid treatments have provoked the hypothesis that EL
60 89 demonstrated a survival disadvantage with steroid treatment (I2 = 14%; relative benefit, 0.89 [CI,
61 The initial rejection episode responded to steroid treatment in 93.4% (tacrolimus) and 63.8% (CsA-M
63 several side effects limit the usefulness of steroid treatment in humans leading to the quest for dev
67 ined, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB
68 ps and then tested the rats during week 2 of steroid treatment in the eight-arm radial-arm version of
71 vertigo, recent evidence suggests that early steroid treatment in vestibular neuritis may improve lon
72 well as topical and anterior subconjunctival steroid treatments in uveitis induced by the intravitrea
74 osite effects on Lep transcript abundance to steroid treatments, indicating that these transcriptiona
76 parameters were used to show that intensive steroid treatment induces thymic involution and a profou
77 gh RSV-induced exacerbation was resistant to steroid treatment, inhibition of TNF-alpha and MCP-1 fun
78 of a net change in cell activity with acute steroid treatment is consistent with the possibility tha
79 s from early B-lineage cells,and response to steroid treatment is critical to successful ALL therapy.
83 oretical analysis of the data suggested that steroid treatment leads to receptors with a greater stab
85 y not only increase our understanding of the steroid treatment mechanism but also help us to better m
88 ational follow-up of the Multicenter Uveitis Steroid Treatment (MUST) randomized clinical trial compa
91 educing AECOPD requiring both antibiotic and steroid treatment (n = 1,113; cumulative incidence analy
98 r133, we also evaluated the effects of acute steroid treatment on levels of phosphorylated CREB (pCRE
100 used to determine the effects of axotomy and steroid treatment on ribosomal transcription and process
103 periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting im
104 rse-effect profile than conventional topical steroid treatments or other medical or surgical therapie
105 sk factors include bisphosphonate treatment, steroid treatment, osteoporosis, and head/neck radiation
109 le disease and with the level of maintenance steroid treatment required to control inflammatory activ
110 V acute graft-versus-host disease related to steroid treatment shows a trend toward a protective effe
114 raftment (T3), at GvHD onset (T4), and after steroid treatment (T5) in 40 patients (7 Hodgkin's Disea
115 d in 54% of biopsies) was less responsive to steroid treatment than rejection without endarteritis, a
118 nd after 2 weeks of systemic glucocorticoid (steroid) treatment to identify immunological differences
120 and biases of recent low-dose (physiologic) steroid treatment trials limit their ability to provide
121 Despite similar baseline clinical severity, steroid treatment was associated with decreased 28-day s
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。